Sm08502-onc-01
Webb27 jan. 2024 · SAN DIEGO, Jan. 27, 2024 /PRNewswire/ -- Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK … Webb31 mars 2024 · In an iterative screening campaign of >1500 compounds, SM08502 was developed as a small-molecule CLK inhibitor with IC 50 values of 0.002 μM for CLK2 and …
Sm08502-onc-01
Did you know?
Webb27 jan. 2024 · As part of this relationship, Biosplice will leverage Epic's comprehensive platform to characterize drug activity and patient response in Biosplice's SM08502-ONC-01 and SM08502-ONC-03 trials. "We are excited to partner with Epic in our biomarker development program" states Darrin Beaupre , MD, PhD, Chief Medical Officer, Oncology … Webb5 nov. 2024 · Carine Bossard, Elizabeth A. McMillan, Emily Creger, Brian Eastman, Chi-Ching Mak, Darrin M. Beaupre, Michael A. White; The Pan-Clk/Dyrk Inhibitor Cirtuvivint …
Webb6 jan. 2024 · Mel J. Yeates. SAN DIEGO—In late 2024, Samumed, LLC noted the publication of data demonstrating a novel mechanism of action for SM08502 in preclinical … Webb17 nov. 2024 · Drug: SM08502 Study Type Interventional Enrollment (Actual) 82 Phase Phase 1 Contacts and Locations This section provides the contact details for those …
WebbSM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, demonstrates strong antitumor effects and Wnt pathway inhibition in castration-resistant prostate cancer … Webb[VIRTUAL] SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, demonstrates strong antitumor effects and Wnt pathway inhibition in castration-resistant prostate …
Webb(C) SM08502 is more potent than PRI-724 in an SW480 Wnt reporter (TOPflash) assay. Cells were treated with a 3-fold 10-point titration of doses of SM08502 or PRI-724 …
Webb1 aug. 2024 · HEC265, SNGM, and Ishikawa-S33Y tumors all had significantly lower tumor volumes with combination of SM08502 and paclitaxel compared to single-agent … toys r us credit applicationWebb26 maj 2024 · Conclusions: In preclinical CRC models, SM08502 was a potent inhibitor of Wnt pathway signaling and gene expression. It showed strong antitumor activity in … toys r us crawling baby dollWebbApply to this Phase 1 clinical trial treating Non-small Cell Lung Cancer, Colorectal Carcinoma (CRC), Castration-resistant Prostate Cancer. Get access to cutting edge … toys r us craneWebbCirtuvivint (SM08502) is a potent and orally active CDC-like kinase (CLK) inhibitor. Cirtuvivint can be used for solid tumors research [1] . Cirtuvivint (SM08502) inhibits … toys r us credit card synchrony loginWebb27 jan. 2024 · As part of this relationship, Biosplice will leverage Epic’s comprehensive platform to characterize drug activity and patient response in Biosplice’s SM08502-ONC … toys r us credit card account loginWebb27 jan. 2024 · Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major diseases, and … toys r us credit card make payment synchronyWebbCancer stem cells (CSCs) are a subpopulation of tumor cells that can drive tumor initiation and can cause relapses. These cells are seen as drivers of tumor establishment and growth, often correlated to aggressive, heterogeneous and therapy-resistant tumors. Novel tumor-specific antigens (TSAs) and tumor-associated antigens (TAAs) specifically … toys r us credit card pay bill online